{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:54:55Z","timestamp":1787064895492,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.lungcan.2023.107379","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:06:04Z","timestamp":1695341164000},"page":"107379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study"],"prefix":"10.1016","volume":"185","author":[{"given":"Lionel","family":"Falchero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Guisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Darrason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Dayen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Cousin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Merle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gine","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Madroszyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josiane","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Tomasini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Assoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Canellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radj","family":"Gervais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Hureaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Le Treut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Naltet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Tiercin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Van Hulst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Missy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Westeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9909-2299","authenticated-orcid":false,"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.lungcan.2023.107379_b0005","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nrc.2017.87","article-title":"Small-cell lung cancer: what we know, what we need to know and the path forward","volume":"17","author":"Gazdar","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2023.107379_b0010","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jtho.2015.10.008","article-title":"The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer","volume":"11","author":"Nicholson","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2023.107379_b0015","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"ESMO Guidelines Committee. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107379_b0020","article-title":"Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages","volume":"7","author":"Wang","year":"2017","journal-title":"Sci. Rep."},{"issue":"23","key":"10.1016\/j.lungcan.2023.107379_b0025","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107379_b0030","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2023.107379_b0035","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower-133)","volume":"39","author":"Liu","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107379_b0040","unstructured":"https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sclc.pdf. Accessed 15th Nov 2022."},{"key":"10.1016\/j.lungcan.2023.107379_b0045","doi-asserted-by":"crossref","first-page":"S1248","DOI":"10.1016\/j.annonc.2022.07.1628","article-title":"1533P - Atezolizumab (ATZ) plus carboplatin (Cb) and etoposide (eto) in patients with untreated extensive-stage small cell lung cancer (ES-SCLC): Results from the interim analysis of MAURIS trial","volume":"33","author":"Bria","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2023.107379_b0050","doi-asserted-by":"crossref","first-page":"S1247","DOI":"10.1016\/j.annonc.2022.07.1627","article-title":"1532P - Phase IIIb study of durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Preliminary efficacy results","volume":"33","author":"Isla","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2023.107379_b0055","doi-asserted-by":"crossref","first-page":"S1250","DOI":"10.1016\/j.annonc.2022.07.1633","article-title":"1539P - Real world (RW) outcomes of second-line (2L) small cell lung cancer (SCLC) patients treated with lurbinectedin","volume":"33","author":"Estrin","year":"2022","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2023.107379_b0060","doi-asserted-by":"crossref","first-page":"353","DOI":"10.21147\/j.issn.1000-9604.2022.04.04","article-title":"Clinical outcomes of atezolizumab in combination with etoposide\/platinum for treatment of extensive-stage small-cell lung cancer: A real-world, multicenter, retrospective, controlled study in China","volume":"34","author":"Chen","year":"2022","journal-title":"Chin. J. Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2023.107379_b0065","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.lungcan.2010.06.003","article-title":"Characteristics, treatment patterns and outcomes of patients with small cell lung cancer\u2013a retrospective single institution analysis","volume":"71","author":"Hermes","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2023.107379_b0070","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1111\/1759-7714.13977","article-title":"Survival and pretreatment prognostic factors for extensive-stage small cell lung cancer: A comprehensive analysis of 358 patients","volume":"12","author":"Huang","year":"2021","journal-title":"Thorac Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2023.107379_b0075","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/0284186X.2019.1711165","article-title":"Treatment patterns and survival outcomes for small-cell lung cancer patients - a Swedish single center cohort study","volume":"59","author":"Tendler","year":"2020","journal-title":"Acta Oncol."},{"key":"10.1016\/j.lungcan.2023.107379_b0080","first-page":"101012","article-title":"Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy","volume":"84","author":"Valette","year":"2023","journal-title":"Respir Med Res."},{"key":"10.1016\/j.lungcan.2023.107379_b0085","doi-asserted-by":"crossref","first-page":"1002385","DOI":"10.3389\/fonc.2022.1002385","article-title":"Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer","volume":"12","author":"Rittberg","year":"2022","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2023.107379_b0090","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(20)30461-7","article-title":"Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial","volume":"21","author":"Baize","year":"2020","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2023.107379_b0095","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s11060-022-04111-7","article-title":"Outcomes of first-line anti-PD-L1 blockades combined with brain radiotherapy for extensive-stage small-cell lung cancer with brain metastasis","volume":"159","author":"Ma","year":"2022","journal-title":"J. Neurooncol"},{"issue":"1","key":"10.1016\/j.lungcan.2023.107379_b0100","doi-asserted-by":"crossref","first-page":"100353","DOI":"10.1016\/j.esmoop.2021.100353","article-title":"IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer","volume":"7","author":"Molinier","year":"2022","journal-title":"ESMO Open."},{"key":"10.1016\/j.lungcan.2023.107379_b0105","doi-asserted-by":"crossref","first-page":"102894","DOI":"10.1016\/j.critrevonc.2020.102894","article-title":"The use of radiation therapy for oligoprogressive\/oligopersistent oncogene-driven non small cell lung cancer: State of the art","volume":"148","author":"Franceschini","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.lungcan.2023.107379_b0110","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.6004\/jnccn.2021.7105","article-title":"Role of Prophylactic Cranial Irradiation in Extensive-Stage Small Cell Lung Cancer","volume":"19","author":"Yu","year":"2021","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.lungcan.2023.107379_b0115","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.lungcan.2017.03.007","article-title":"Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial","volume":"108","author":"Slotman","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2023.107379_b0120","doi-asserted-by":"crossref","first-page":"S1421","DOI":"10.1016\/j.annonc.2022.08.056","article-title":"LBA54 - Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial","volume":"33","author":"\u00d6zg\u00fcro\u011flu","year":"2022","journal-title":"Ann. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223009170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223009170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:05:23Z","timestamp":1759237523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223009170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":24,"alternative-id":["S0169500223009170"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107379","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107379","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107379"}}